J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
This article was originally published in The Pink Sheet Daily
Acquisition could bolster the stent portfolio of Johnson & Johnson's Cordis unit, helping it retain top-tier market share as a flurry of new competitors joins the market. Conor expects to submit an application to FDA next year for its paclitaxel-eluting, cobalt-chromium coronary stent with a bioabsorbable polymer coating, which has yet to show any cases of late stent thrombosis in clincial trials.
You may also be interested in...
The government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies
The San Diego firm is diversifying its spinal fusion offerings with a $16 million purchase of the Formagraft synthetic bone graft product line.
Needle-free drug-delivery system manufacturer needs to generate $3 mil. in a financing round in order to continue operations past May 31.